#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3266	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2307	255.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1754	1754	T	320	T	188	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3266	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2307	255.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1488	1488	C	377	C	220	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3778	282.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1769	1769	A	326	A	196	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3778	282.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2403	2403	C	327	C	198	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3778	282.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2477	2477	A	349	A	220	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3778	282.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3029	3029	C	392	C,A	234,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	242	folP	855	855	100.0	folP.l15.c4.ctg.1	1636	27.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1002	1004	AGC	39;40;40	A;G;C	27;28;25	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	706	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3548	35.5	1	SNP	p	S91F	1	.	.	271	273	TTC	725	727	TTC	61;61;61	T;T;C	35;36;37	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	706	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3548	35.5	1	SNP	p	G95N	0	.	.	283	285	GGC	737	739	GGC	66;67;67	G;G;C	39;40;39	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	706	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3548	35.5	1	SNP	p	D95G	1	.	.	283	285	GGC	737	739	GGC	66;67;67	G;G;C	39;40;39	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	188	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1165	30.5	1	SNP	p	G45D	0	.	.	133	135	GGC	387	389	GGC	41;41;41	G;G;C	27;25;25	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	144	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	935	26.8	0	.	n	.	0	A197.	DEL	197	197	A	535	535	A	52	A	32	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	538	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2674	35.2	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1346	1348	GTC	42;42;42	G;T;C	30;29;30	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	538	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2674	35.2	1	SNP	p	D86N	0	.	.	256	258	GAC	452	454	GAC	40;40;40	G;A;C	27;22;24	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	538	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2674	35.2	1	SNP	p	R87I	0	.	.	259	261	CGT	455	457	CGT	40;40;41	C,A;G;T	25,1;24;25	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	538	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2674	35.2	1	SNP	p	S87R	1	.	.	259	261	CGT	455	457	CGT	40;40;41	C,A;G;T	25,1;24;25	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	538	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2674	35.2	1	SNP	p	R87W	0	.	.	259	261	CGT	455	457	CGT	40;40;41	C,A;G;T	25,1;24;25	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	538	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2674	35.2	1	SNP	p	S88P	0	.	.	262	264	TCC	458	460	TCC	41;41;41	T;C;C	25;26;28	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	414	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2725	27.7	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1450	1452	TGC	23;23;21	T;G;C	14;15;13	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	414	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2725	27.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1660	1662	GGC	22;22;20	G;G;C	15;13;14	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1186	1188	GCA	64;65;65	G;C;A	42;41;38	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1189	1191	ATC	68;68;68	A;T;C	43;42;44	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1201	1203	GTG	74;74;74	G;T;G	47;45;48	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1201	1203	GTG	74;74;74	G;T;G	47;45;48	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1705	1707	ACC	27;27;27	A;C;C	15;17;18	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1759	1761	GCG	22;22;22	G;C;G	14;13;13	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1759	1761	GCG	22;22;22	G;C;G	14;13;13	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1882	1884	GGC	16;16;17	G;G;C	12;11;10	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1891	1893	GGC	14;14;14	G;G;C	10;10;8	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	558	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2186	44.0	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1909	1911	TCG	15;15;15	T;C;G	8;9;8	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1212	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3131	63.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1686	1688	CCG	39;39;39	C;C;G	27;30;26	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	256	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1625	29.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	436	436	C	24	C	14	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	444	446	GAA	56;52;53	G;A;A	34;33;34	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	732	734	GAT	52;52;52	G;A;T	30;30;31	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	855	857	TCA	56;56;56	T;C;A	33;33;33	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	984	986	GTC	31;31;31	G;T;C	17;19;18	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1206	1208	ACT	51;51;50	A;C;T	30;31;30	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1314	1316	GCA	56;56;54	G;C;A	38;38;36	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	1	SNP	p	G120K	1	.	.	358	360	AAG	690	692	AAG	41;41;43	A;A;G	25;25;25	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	1	SNP	p	D121N	0	.	.	361	363	GAC	693	695	GAC	45;45;45	G;A;C	26;26;26	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	370	porB1b	1047	1047	99.24	porB1b.l6.c17.ctg.1	2082	30.5	1	SNP	p	A121D	1	.	.	361	363	GAC	693	695	GAC	45;45;45	G;A;C	26;26;26	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1582	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5305	51.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2248	2250	AAT	83;82;82	A;A;T	50;49;47	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	118	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1083	21.1	1	SNP	p	V57M	1	.	.	169	171	ATG	605	607	ATG	43;43;43	A;T;G	27;28;28	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
